Predictive Oncology Reports Significant Revenue Decline and Net Loss in Q2 2025

Predictive Oncology Inc. reported a significant decline in financial performance for the second quarter of 2025, with revenues dropping to $2,682 compared to $67,255 in the same period of 2024. For the first half of 2025, the company generated $112,992 in revenue, an increase from $72,113 in the prior year, primarily attributed to the completion of a tumor-specific 3D model. However, the overall financial picture remains concerning, as the company recorded a net loss of $2,070,462 for the quarter, down from a loss of $3,181,261 in the previous year. The accumulated deficit as of June 30, 2025, stood at $184,939,606.

The company's operational metrics reflect ongoing challenges. Total operating expenses for the second quarter were $2,644,329, slightly higher than the $2,518,052 reported in the same quarter of 2024. General and administrative expenses increased to $1,875,655, while sales and marketing expenses rose to $268,959, reflecting increased digital marketing efforts. The company also reported a notable increase in other income, which reached $682,424, primarily due to the write-off of aged accounts payable.

In terms of strategic developments, Predictive Oncology has undergone significant organizational changes, including the discontinuation of its Eagan operating segment, which was sold to DeRoyal Industries for $625,000 in March 2025. This decision was part of a broader strategy to focus on its core business of applying artificial intelligence to cancer therapy development. The company also entered into a standby equity purchase agreement with Yorkville, allowing it to sell up to $10 million in shares, which is critical for addressing its liquidity needs.

As of June 30, 2025, Predictive Oncology had cash and cash equivalents of $506,078, a decrease from $611,822 at the end of 2024. The company reported negative cash flows from continuing operations of $4,280,632 for the first half of 2025, although this was an improvement compared to $5,504,158 in the same period of 2024. The company faces substantial doubt about its ability to continue as a going concern, given its ongoing losses and need for additional capital to sustain operations.

Looking ahead, Predictive Oncology is actively exploring various financing options to bolster its liquidity and operational capacity. The company is also seeking to regain compliance with Nasdaq listing requirements, having received an extension until December 8, 2025, to meet the necessary standards. Despite these efforts, the company acknowledges the uncertainty surrounding its future financial stability and operational viability.